Supplement Figure 4
Supplement Figure 7

A

B

A549

SPCA-1

374+DDP

374+NS

NC+DDP

NC+NS

H1975-NC

H1975-miR-374a

H1975-miR-374a+PTEN

pc-9-NC

pc-9-miR-374a

pc-9-miR-374a+CCND1

Fraction surviving

Fraction surviving

DDP (µM)

DDP (µM)

Cum Survival

days

days
Supplementary Table 1. The expression of miR-374a in non-small cell lung cancer (NSCLC) and paracancerous tissue (PT).

| Group | Cases (n) | Protein expression (n) |     | P value |
|-------|-----------|------------------------|-----|---------|
|       |           | Low expression         |     |         |
| NSCLC | 158       | 44 (27.8%)             | 114 (72.2%) | 0.000   |
| PT    | 158       | 99 (62.7%)             | 59 (37.3%)  |         |
Supplementary Table 2. Correlation between the clinicopathologic characteristics and expression of miR-374a in NSCLC.

| Characteristics        | N   | Low expression | High expression | P value |
|------------------------|-----|----------------|-----------------|---------|
| Age                    |     |                |                 |         |
| < 60                   | 70  | 24 (34.3%)     | 46 (65.7%)      | 0.109   |
| ≥ 60                   | 88  | 20 (22.7%)     | 68 (77.3%)      |         |
| Gender                 |     |                |                 |         |
| Male                   | 83  | 19 (22.9%)     | 64 (77.1%)      | 0.145   |
| Female                 | 75  | 25 (30.1%)     | 50 (66.7%)      |         |
| FIGO stage             |     |                |                 |         |
| I -II                  | 81  | 24 (29.6%)     | 57 (70.4%)      | 0.610   |
| III-IV                 | 77  | 20 (26.0%)     | 57 (74.0%)      |         |
| T                      |     |                |                 |         |
| T1-T2                  | 74  | 21 (28.4%)     | 53 (71.6%)      | 0.396   |
| T3-T4                  | 84  | 23 (27.4%)     | 61 (72.6%)      |         |
| N                      |     |                |                 |         |
| N0-N1                  | 87  | 30 (34.5%)     | 57 (65.5%)      | 0.040   |
| N2-N3                  | 71  | 14 (19.7%)     | 57 (80.3%)      |         |
| M                      |     |                |                 |         |
| M0                     | 154 | 42 (27.3%)     | 112 (72.7%)     | 0.318   |
| M1                     | 4   | 2 (50%)        | 2 (50%)         |         |
Supplementary Table 3 Summary of univariate and multivariate Cox regression analysis of overall survival duration

| Parameter                      | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | P      | HR   | 95%CI   | P      | HR   | 95%CI   |
| Age <60 vs. ≥60               | 0.005  | 1.873| 1.209-2.901 | 0.375  | 1.456| 0.635-3.340 |
| Gender Male vs. Female        | 0.065  | 1.481| 0.976-2.247 |
| FIGO stage I-II vs. III-IV    | 0.007  | 1.793| 1.177-2.733 | 0.832  | 0.000| 0.000-9.588E |
| T T1-T2 vs. T3-T4             | 0.187  | 1.324| 0.873-2.008 |
| N N0-N1 vs. N2-N3             | 0.000  | 2.302| 1.509-3.512 | 0.824  | 1.162E| 0.000-8.381E |
| M M0 vs. M1                   | 0.484  | 0.606| 0.149-2.464 |
| miR-374a expression Low vs. high | 0.041  | 1.696| 1.021-2.819 | 0.221  | 1.379| 0.824-2.308 |
Supplementary Table 4. The primers used in this study.

|                | Sequence                              |
|----------------|---------------------------------------|
| **miR-374a**   | Sense 5’ CGGCGGTTATAATACAACCTG3’      |
|                | Antisense ----                        |
| **U6**         | Sense 5’ CTCGCTTCGGCAGCACATATA3’      |
|                | Antisense ----                        |
| **c-Jun**      | Sense 5’ CTGCCTTTACAGTCTGGGAG3’       |
|                | Antisense 3’ CTCGCCCAAGTTCAACAA5’     |
| **ARF5**       | Sense 5’ ATCTGTTCACAGTCTGGGAG3’       |
|                | Antisense 3’ CCTGCTTTGTTGGCAATACC5’   |
| **CCND1 3’ UTR** | Sense 5’ ATCGCTCGAGACAAAGGAGGCGTCTCGG 3’ |
|                | Antisense 3’ ATCGCGGCCGCCGCTAGGAGTGGGACAGGTGGC5’ 5’ |
| **PTEN 3’ UTR** | Sense 5’ ATCGCTCGAGAGGAGGCGTCTGGGAG3’ |
|                | Antisense 3’ ATCGCGGCCGCCGCTAGGAGTGGGAGCCTG5’ |
| **CHIP-1**     | Sense 5’ TTGCCCATTGAGTCTGAAGAAATG3’   |
|                | Antisense 3’ CAAGGCGTGGTGAAGGTGGC5’   |
| **CHIP-2**     | Sense 5’ GATGTGAAATGCTAATAGGAAC3’     |
|                | Antisense 3’ GCAAATAAGGGCTGATAACATCA5’ |
| **Promotor-miR-374a** | Sense 5’ ATCCCTCGAGTTGCCATGCTTGAAGAAATG3’ |
|                | Antisense 3’ ATCGCGGCCGCCAATAAGGGCTGATAACATCA5’ |
Supplementary Table 5. The sequences used in this study.

|            | Sequence                                      |
|------------|-----------------------------------------------|
| c-JUN      | Sense 5’ CGCAGCAGUUGCAAACAUU dTdT 3’          |
|            | Antisense 3’ dTdT GCGUCGUAACGCUUUGUAA 5’      |
| CCND1      | Sense 5’ UGGAAUAGCUUCUGGAUU dTdT 3’           |
|            | Antisense 3’ dTdT ACCUUAUCGAAGACCUUAA 5’      |
| PTEN       | Sense 5’ AGGACAGCUCUAUGUACUU dTdT 3’          |
|            | Antisense 3’ dTdT AAGUAACGAUGCUUUGUCCU 5’     |
| miR-374a   | Sense 5’ UUAUAUAACAACCUGUAUAGUG 3’            |
| mimics     | Antisense 3’ AAUAUUAUGUUGGACUAUUCAC 5’        |
| Negative   | Sense 5’ UUUGUACUACACAAAAGUACUG 3’            |
| control    | Antisense 3’ AAACUGAUGUGUUUUCUGAC 5’          |
| miR-374a   | 5’CACUUACAGGUUGUAUUAADA 3’                    |
| inhibitor  |                                              |
| Negative   | 5’ CAGUACUUUUGUGUAGUACAAA 3’                  |
| control    |                                              |